Clinical Corner
BMT Reunion 2018
Clinical Corner
UF Health's 16th Bone Marrow Transplant Reunion
On June 23, UF Health hosted its 16th Bone Marrow Transplant Reunion.
The University of Florida Health Bone Marrow Transplant Reunion is held every two years to bring together transplant survivors, their families, caregivers and donors for a day of celebration of life, survival, food, education and fun. As many as 500 patients, caregivers, donors, volunteers and staff members attend each year.
The Blood and Marrow Transplant Program at UF Health is the state’s first and most successful transplant program, having completed more than 3,200 transplants for both adult and pediatric patients for diseases such as leukemia, multiple myeloma, lymphomas, neuroblastoma, myelodysplastic syndromes, testicular cancer, aplastic anemia, certain genetic disorders and immunodeficiency syndromes. The patient outcomes for this program are ranked among the top 2.5 percent nationwide.
The event, which was closed to the public, included speakers, live music, lunch, a magic show, a slideshow and a story-telling segment.
“Nearly 500 of our patients and families and our staff gathered together in a glorious occasion devoted to healing and making joyful connections,” John Wingard, M.D., said. “We shared moments of joy, moments of sadness, we honored the memory of those whom we lost along the way. We discovered musical and magical talents among our extended family, we heard from the patients how much we really mean to them, how interconnected we all are.”
To view the full photo gallery from the BMT reunion, click here.
See the coverage by TV-20 here.
Clinical Trial Highlight: Refractory Cancers
This issue of the UFHCC Connection highlights clinical trials currently recruiting patients with refractory malignancies.
Questions about how to send a patient? Please contact the Clinical Trials Office at cancer-center@ufl.edu
or 352.273.8675
This Phase 2 trial is available for patients with relapse/refractory Multiple Myeloma who have received 1-4 lines of therapy. Patients must have been exposed to an IMID and whose disease is not Bortezomib-refractory.
This is an open-label Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of NLG802, an investigational agent intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme and help the human immune system attack solid tumor cells more effectively.
This Phase 1/2 trial is available for most patients with advanced solid tumors refractory to standard therapies. It tests the combination of dual DNA-repair/replication inhibitors, even if the cancer type is not typically sensitive to irinotecan.